John L Hopper
John L Hopper
A first-degree relative of an individual with colorectal cancer is on average at about a twofold increased risk. This could not occur without there being strong underlying risk factors that are correlated in relatives. About 90% of colorect...
Peter Greenwald
Peter Greenwald
Cancer risk can be reduced by adopting a healthy lifestyle and by medical means. Tobacco control is central to public policies for cancer prevention. Overweight and obesity in the United States may contribute to 20% of cancer deaths in wome...
Mechanisms implicated in the growth regulatory effects of vitamin D compounds in breast cancer cells [0.03%]
维生素D衍生物抑制乳腺癌细胞增殖的作用机制研究
Lorraine Lowe,Christina Mørk Hansen,Siddhika Senaratne et al.
Lorraine Lowe et al.
The active metabolite of vitamin D3, 1,25-dihydroxyvitamin D3 (1,25(OH)D3), has been recognized for over 2 decades as a modulator of cell proliferation and differentiation in many cell types, including breast cancer. However, any potential ...
Is FOB screening really the answer for lowering mortality in colorectal cancer? [0.03%]
FOB筛检真的能够降低结直肠癌的死亡率吗？
Philippe Autier,Peter Boyle,Marc Buyse et al.
Philippe Autier et al.
In the three trials that tested screening with biennial fecal occult blood test (FOBT), follow-up of control patients for colorectal cancer (CRC) differed: in the Minnesota (United States) trial, the follow-up was equivalent to patients in ...
Gad Rennert
Gad Rennert
Colorectal cancer is a leading cause of morbidity and mortality in Western countries. Primary prevention and early detection of this malignancy has been shown in multiple research set-ups, and using different modalities, to be effective in ...
Genetic predisposition as a basis for chemoprevention, surgical and other interventions in colorectal cancer [0.03%]
结直肠癌的化学预防及基因易感性的基础外科和其他干预措施
Hansjakob Müller,Martina Plasilova,Anna Marie Russell et al.
Hansjakob Müller et al.
Strategies of cancer prevention are generally developed with the population at large in mind. However, special attention is warranted for those persons with rare genetic traits associated with a greatly elevated risk of developing colorecta...
Hans-Peter Schmid,Ladislav Prikler,Axel Semjonow
Hans-Peter Schmid
The effect of population screening with regard to reduction of prostate cancer specific mortality and quality of life issues is not yet clear. Several national and international prospective studies are currently being conducted to answer th...
Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial [0.03%]
前列腺癌化学预防药物检验的临床模型及SELECT研究概述（一项硒和维生素E癌症预防试验）
Eric A Klein
Eric A Klein
Target populations for chemoprevention trials should include those at higher than average risk for the development of prostate cancer as defined by explicit epidemiologic and genetic criteria. Such populations include a "primary prevention"...
Prevention of prostate cancer [0.03%]
前列腺癌的预防
Claude C Schulman,Alexandre R Zlotta
Claude C Schulman
Prostate cancer is an ideal candidate for chemoprevention because of its high prevalence, long latency time, hormone dependency, precursor lesions, and its unique serum marker, PSA. Chemoprevention is the administration of drugs or other ag...